hancock jaffe laboratories, inc. is a medical device company based out of 2807 mcgaw ave, irvine, ca, united states.
Company profile
Ticker
NVNO
Exchange
Website
CEO
Robert Andrew Berman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Hancock Jaffe Laboratories, Inc.
SEC CIK
Corporate docs
Subsidiaries
Hancock Jaffe Laboratories Vascular, Inc. ...
NVNO stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
24 Apr 24
8-K
Regulation FD Disclosure
6 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
7 Dec 23
8-K
Regulation FD Disclosure
16 Nov 23
EFFECT
Notice of effectiveness
6 Nov 23
DEF 14A
Definitive proxy
3 Nov 23
CORRESP
Correspondence with SEC
1 Nov 23
UPLOAD
Letter from SEC
31 Oct 23
S-3
Shelf registration
26 Oct 23
Latest ownership filings
4
Hamed Alavi
15 Mar 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
23 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
4
Craig Glynn
7 Dec 23
4
Matthew Jenusaitis
7 Dec 23
4
Hamed Alavi
7 Dec 23
4
Marc H. Glickman
7 Dec 23
4
Robert Gray
7 Dec 23
4
Sanjay Shrivastava
7 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.95 mm | 4.95 mm | 4.95 mm | 4.95 mm | 4.95 mm | 4.95 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.78 mm | 2.12 mm | 1.40 mm | 1.48 mm |
Cash used (since last report) | n/a | n/a | 12.20 mm | 14.49 mm | 9.61 mm | 10.11 mm |
Cash remaining | n/a | n/a | -7.25 mm | -9.54 mm | -4.66 mm | -5.17 mm |
Runway (months of cash) | n/a | n/a | -4.1 | -4.5 | -3.3 | -3.5 |
Institutional ownership, Q2 2023
19.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 23 |
Opened positions | 4 |
Closed positions | 0 |
Increased positions | 5 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 5.82 bn |
Total shares | 2.61 mm |
Total puts | 1.40 k |
Total calls | 5.30 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 781.62 k | $2.41 bn |
Intracoastal Capital | 431.21 k | $2.84 mm |
Vanguard | 335.80 k | $1.03 bn |
CVI Investments | 280.36 k | $0.00 |
Kingdon Capital Management, L.L.C. | 219.18 k | $675.07 mm |
Ubs Oconnor | 186.81 k | $575.39 mm |
Geode Capital Management | 83.08 k | $255.90 mm |
Susquehanna International | 64.25 k | $197.88 mm |
Citadel Advisors | 45.09 k | $138.87 mm |
MS Morgan Stanley | 36.99 k | $113.92 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Hamed Alavi | Common Stock | Sell | Dispose S | No | No | 6.22 | 8,334 | 51.84 k | 0 |
13 Mar 24 | Hamed Alavi | Common Stock | Option exercise | Acquire M | No | No | 3.59 | 8,334 | 29.92 k | 8,334 |
13 Mar 24 | Hamed Alavi | Stock Options Common Stock | Option exercise | Dispose M | No | No | 3.59 | 8,334 | 29.92 k | 91,666 |
5 Dec 23 | Matthew Jenusaitis | Stock Options Common Stock | Grant | Acquire A | No | No | 3.59 | 13,856 | 49.74 k | 13,856 |
5 Dec 23 | Hamed Alavi | Stock Options Common Stock | Grant | Acquire A | No | No | 3.59 | 100,000 | 359.00 k | 100,000 |
5 Dec 23 | Berman Robert Andrew | Stock Options Common Stock | Grant | Acquire A | No | No | 3.59 | 300,000 | 1.08 mm | 300,000 |
5 Dec 23 | Craig Glynn | Stock Options Common Stock | Grant | Acquire A | No | No | 3.59 | 75,000 | 269.25 k | 75,000 |
Press releases
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
24 Apr 24
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
16 Apr 24
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
9 Apr 24
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
6 Mar 24